1. Treatment

    Comments Leave a Comment

    1-15 of 337 1 2 3 4 ... 21 22 23 »
    1. Mentioned In 337 Articles

    2. Modulation of interactions of neuroblastoma cell lines with extracellular matrix proteins affects their sensitivity to treatment with the anti-GD2 ganglioside antibody 14G2a.

      ...t of neuroblastoma cells to extracellular matrix (ECM) proteins can affect their sensitivity to the 14G2a mAb treatment. First, using ultra-low attachment plates, we show that survival of the IMR-32, LA-N-1, LA-N-5, CHP-...
      Read Full Article
      Mentions: Antibody Treatment
    3. Dinutuximab for maintenance therapy in pediatric neuroblastoma.

      ...harmacology, clinical efficacy, safety, dosage and administration, and role in therapy of dinutuximab for the treatment of high-risk pediatric neuroblastoma are reviewed. Dinutuximab (Unituxin, United Therapeutics) is a ...
      Read Full Article
      Mentions: Treatment
    4. ICR scientists awarded £1.5m precision medicine funding for targeted, less toxic childhood cancer treatments

      ICR scientists awarded £1.5m precision medicine funding for targeted, less toxic childhood cancer treatments
      ...r time, with feedback from clinical trials and using expert databases, clinicians will be able to personalise treatment plans to maximise potential for cure and minimise adverse long-term toxic side-effects from the trea...
      Read Full Article
      Mentions: Treatment
    5. EUSA Pharma and Apeiron Biologics Receive Positive CHMP Opinion for dinutuximab beta for the Treatment of High-risk neuroblastoma in Europe

      EUSA Pharma and Apeiron Biologics Receive Positive CHMP Opinion for dinutuximab beta for the Treatment of High-risk neuroblastoma in Europe
      HEMEL HEMPSTEAD, England and VIENNA, March 27, 2017 /PRNewswire/ -- EUSA Pharma (EUSA), a specialty pharmaceutical company with a focus on oncology and oncology supportive care, and Apeiron Biologics today announced that the European Medicines Agency's (EMA) Committee for Medicinal...
      Read Full Article
      Mentions: Treatment
    6. Safe and Effective Treatment of Experimental Neuroblastoma and Glioblastoma Using Systemically Delivered Triple MicroRNA-Detargeted Oncolytic Semliki Forest Virus

      ... Alerts Cancer Therapy: Preclinical Safe and Effective Treatment of Experimental Neuroblastoma and Glioblastoma Using Systemically Delivered Triple MicroRNA-Detargeted Oncolytic Semliki Forest Virus Mohanraj R...
      Read Full Article
    7. 1-15 of 337 1 2 3 4 ... 21 22 23 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Quotes about Treatment

    1. Our data not only identify KIR/KIR-ligand genotypes associated with differences in outcome following treatment with immunotherapy but also indicate that the immune cells that are regulated by KIR/KIR-ligand interactions, namely NK cells, play a major role in mediating the anticancer effects of this immunotherapy treatment.
      In Biomarker may identify neuroblastoma patients most likely to benefit from immunotherapy
    2. The most ominous late effect of pediatric cancer treatment is a second malignancy.
      In Risk of subsequent malignancies reduced among childhood cancer survivors
    3. Our data not only identify KIR/KIR-ligand genotypes associated with differences in outcome following treatment with immunotherapy but also indicate that the immune cells that are regulated by KIR/KIR-ligand interactions, namely NK cells, play a major role in mediating the anticancer effects of this immunotherapy treatment.
      In Biomarker May Identify Neuroblastoma Patients Most Likely to Benefit from Immunotherapy